

Reference: FOI. ICB-2526/301

Subject: Mounjaro (tirzepatide) Prescribing

I can confirm that the ICB does hold the information requested; please see responses below:

| QUESTION | RESPONSE | | | | | | | | | | | | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-----|-----|-----|---|----|----|-----|-----|-----|----|
| <ol style="list-style-type: none"> 1. How many individual patients within the ICB have been prescribed or dispensed Mounjaro (tirzepatide) since the start of the phased rollout on 23 June 2025? 2. If possible, please provide this data broken down by month. | <p>From the date provided, this data assumes the question is asking for tirzepatide prescribing for weight loss in primary care under the NICE TA1026 funding variation.</p> <ol style="list-style-type: none"> 1. Between 23/6/25 – 07/12/25 there were 239 patients with general practice issued prescriptions for tirzepatide who had a code of “NHS medication pathway started” 2. As per criteria in 1. Patients per month, note December is only 1/12/25 – 7/12/25 <table border="1"> <thead> <tr> <th>Jun</th><th>Jul</th><th>Aug</th><th>Sep</th><th>Oct</th><th>Nov</th><th>Dec</th></tr> </thead> <tbody> <tr> <td>8</td><td>41</td><td>86</td><td>117</td><td>168</td><td>193</td><td>55</td></tr> </tbody> </table> | Jun | Jul | Aug | Sep | Oct | Nov | Dec | 8 | 41 | 86 | 117 | 168 | 193 | 55 |
| Jun | Jul | Aug | Sep | Oct | Nov | Dec | | | | | | | | | |
| 8 | 41 | 86 | 117 | 168 | 193 | 55 | | | | | | | | | |
| 3. If your ICB is not currently prescribing tirzepatide (Mounjaro), when will it be available? | N/A | | | | | | | | | | | | | | |
| 4. How many patients within the ICB and associated specialist weight management services are currently being prescribed WeGovy (semaglutide)? | 1104 (April 25 to Oct 25) | | | | | | | | | | | | | | |

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>5. What BMI does someone need to have to be eligible for WeGovy (semaglutide) within the ICB and associated specialist weight management services?</p> | <p>Access to Specialist Weight Management Services (SWMS) is subject to a criteria based access policy which can be found Weight Management Service - Tier 3 and Tier 4 Service - BNSSG Healthier Together</p> <p>Patients meeting the Tier 3/4 eligibility criteria with a BMI of 35 or more may then be assessed by the specialist weight management team and offered semaglutide as per the NICE TA875</p> |
| <p>6. Has that BMI eligibility for WeGovy (semaglutide) changed over time? If yes, please state by date when the change was made and what the BMI eligibility is/was.</p> | <p>The BMI eligibility for WeGovy (semaglutide) has not changed over time.</p> <p>The history of the policy for access to SWMS and associated amendments are detailed on page 2.</p> |

The information provided in this response is accurate as of 30 December 2025 and has been approved for release by Debbie Campbell, Chief Pharmacist and Director of Medicines Optimisation for NHS Bristol, North Somerset and South Gloucestershire ICB.